Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
Sarcopenia is common in metastatic colorectal cancer (mCRC), increases the risk of treatment-related toxicity and reduces survival. Trifluridine/tipiracil (TT) chemotherapy significantly improved survival in refractory mCRC patients, but the prognostic and predictive role of pretherapeutic sarcopeni...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a4d0d1c41af74f5a98c83cefe33c0f6c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a4d0d1c41af74f5a98c83cefe33c0f6c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a4d0d1c41af74f5a98c83cefe33c0f6c2021-11-11T17:43:38ZPrognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil10.3390/jcm102151072077-0383https://doaj.org/article/a4d0d1c41af74f5a98c83cefe33c0f6c2021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/5107https://doaj.org/toc/2077-0383Sarcopenia is common in metastatic colorectal cancer (mCRC), increases the risk of treatment-related toxicity and reduces survival. Trifluridine/tipiracil (TT) chemotherapy significantly improved survival in refractory mCRC patients, but the prognostic and predictive role of pretherapeutic sarcopenia and variation in the skeletal muscle index (SMI) during this treatment has not been investigated so far. In this retrospective, observational study, clinical data on mCRC patients treated with TT at six cancer centres in Poland were collected. Computed tomography (CT) scans acquired at the time of initiation of TT (CT1) and on the first restaging (CT2), were evaluated. SMI was assessed based on the skeletal muscle area (SMA) at the level of the third lumbar vertebra. Progression-free survival (PFS) and overall survival (OS) were calculated from the treatment start. Neither initial sarcopenia nor ≥5% skeletal mass loss (SML) between CT1 and CT2 had a significant effect on PFS in treated patients (<i>p</i> = 0.5526 and <i>p</i> = 0.1092, respectively). In the multivariate analysis, reduced OS was found in patients with ≥5% SML (HR: 2.03 (1.11–3.72), <i>p</i> = 0.0039). We describe the prognostic role of sarcopenia beyond second line treatment and analyze other factors, such as performance status, tumor histological differentiation or carcinoembryonic antigen level that could predict TT treatment response.Mateusz MalikMaciej MichalakBarbara RadeckaMarek GełejAleksandra JackowskaEmilia Filipczyk-CisarżKatarzyna HetmanMałgorzata Foszczyńska-KłodaBeata Kania-ZembaczyńskaDanuta MańkaMarlena OrlikowskaHanna Rogowska-DrośLubomir BodnarMDPI AGarticlesarcopeniametastatic colorectal cancercancer cachexiatrifluridine/tipiracilMedicineRENJournal of Clinical Medicine, Vol 10, Iss 5107, p 5107 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
sarcopenia metastatic colorectal cancer cancer cachexia trifluridine/tipiracil Medicine R |
| spellingShingle |
sarcopenia metastatic colorectal cancer cancer cachexia trifluridine/tipiracil Medicine R Mateusz Malik Maciej Michalak Barbara Radecka Marek Gełej Aleksandra Jackowska Emilia Filipczyk-Cisarż Katarzyna Hetman Małgorzata Foszczyńska-Kłoda Beata Kania-Zembaczyńska Danuta Mańka Marlena Orlikowska Hanna Rogowska-Droś Lubomir Bodnar Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil |
| description |
Sarcopenia is common in metastatic colorectal cancer (mCRC), increases the risk of treatment-related toxicity and reduces survival. Trifluridine/tipiracil (TT) chemotherapy significantly improved survival in refractory mCRC patients, but the prognostic and predictive role of pretherapeutic sarcopenia and variation in the skeletal muscle index (SMI) during this treatment has not been investigated so far. In this retrospective, observational study, clinical data on mCRC patients treated with TT at six cancer centres in Poland were collected. Computed tomography (CT) scans acquired at the time of initiation of TT (CT1) and on the first restaging (CT2), were evaluated. SMI was assessed based on the skeletal muscle area (SMA) at the level of the third lumbar vertebra. Progression-free survival (PFS) and overall survival (OS) were calculated from the treatment start. Neither initial sarcopenia nor ≥5% skeletal mass loss (SML) between CT1 and CT2 had a significant effect on PFS in treated patients (<i>p</i> = 0.5526 and <i>p</i> = 0.1092, respectively). In the multivariate analysis, reduced OS was found in patients with ≥5% SML (HR: 2.03 (1.11–3.72), <i>p</i> = 0.0039). We describe the prognostic role of sarcopenia beyond second line treatment and analyze other factors, such as performance status, tumor histological differentiation or carcinoembryonic antigen level that could predict TT treatment response. |
| format |
article |
| author |
Mateusz Malik Maciej Michalak Barbara Radecka Marek Gełej Aleksandra Jackowska Emilia Filipczyk-Cisarż Katarzyna Hetman Małgorzata Foszczyńska-Kłoda Beata Kania-Zembaczyńska Danuta Mańka Marlena Orlikowska Hanna Rogowska-Droś Lubomir Bodnar |
| author_facet |
Mateusz Malik Maciej Michalak Barbara Radecka Marek Gełej Aleksandra Jackowska Emilia Filipczyk-Cisarż Katarzyna Hetman Małgorzata Foszczyńska-Kłoda Beata Kania-Zembaczyńska Danuta Mańka Marlena Orlikowska Hanna Rogowska-Droś Lubomir Bodnar |
| author_sort |
Mateusz Malik |
| title |
Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil |
| title_short |
Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil |
| title_full |
Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil |
| title_fullStr |
Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil |
| title_full_unstemmed |
Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil |
| title_sort |
prognostic value of sarcopenia in metastatic colorectal cancer patients treated with trifluridine/tipiracil |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/a4d0d1c41af74f5a98c83cefe33c0f6c |
| work_keys_str_mv |
AT mateuszmalik prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT maciejmichalak prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT barbararadecka prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT marekgełej prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT aleksandrajackowska prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT emiliafilipczykcisarz prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT katarzynahetman prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT małgorzatafoszczynskakłoda prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT beatakaniazembaczynska prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT danutamanka prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT marlenaorlikowska prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT hannarogowskadros prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT lubomirbodnar prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil |
| _version_ |
1718432017315528704 |